Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3446 - The primary prophylaxis of pneumocystis pneumonia by low-dose trimethoprim-sulfamethoxazole during R-CHOP therapy


09 Oct 2016


Poster display


Akiyasu Sato


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


A. Sato1, H. Tsujimura2, K. Ono2, X. Wang2, T. Sugawara2, M. Ise2, K. Kumagai2

Author affiliations

  • 1 Division Of Hematology-oncology, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 2 Division Of Hematology-oncology, Chiba Cancer Center Hospital, Chiba/JP


Abstract 3446


Pneumocystis pneumonia (PCP) is frequently observed in immunocompromised patients. Currently, oral administration of trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 1 tablet daily (7 tablets/week) or 2 tablets twice a day, twice a week (8 tablets/week) is considered as standard for prophylaxis. However, they sometimes induce unpleasant toxicities such as rash, leukopenia and renal dysfunction. To avoid them, dose reduction of TMP-SMX could be considerable. Rituximab plus CHOP therapy (R-CHOP) is a standard treatment for B-cell lymphoma. Since rituximab is immunosuppressive, prophylaxis of PCP is widely introduced. In our institute, low-dose TMP-SMX has been employed in such situations. To assess the efficacy and tolerability of the regimen, retrospective analysis was performed.


We reviewed patients with newly diagnosed B-cell lymphoma who completed 6 to 8 cycles of R-CHOP in our institute. In all patients, low-dose TMP-SMX consisting of 1 tablet twice a day, twice a week (4 tablets/week) was started simultaneously with R-CHOP. To improve medication adherence, administration day was fixed on Tuesday and Friday.


From January 2009 to September 2014, 292 patients with a median age of 67 (21-89) were treated. They included diffuse large B-cell lymphoma (n = 213), follicular lymphoma (n = 65), mantle cell lymphoma (n = 6) and others (n = 8). The median length of prophylaxis from the last day of R-CHOP was 5.7 (0.6-16.6) months. The median lymphocyte count decreased from 1.1 (0.07-19.2) to 0.4 (0.03-1.4) x 109/L during treatment. Of 292 patients, 291 showed no evidence of PCP. Although 1 patient developed PCP, the diagnosis was given on day 12 of the first cycle indicating that the patient already had PCP before the initiation of prophylaxis. In the other 291 patients, TMP-SMX was well tolerated and no related adverse event was observed.


Four tablets of TMP-SMX a week may be sufficient to prevent PCP during R-CHOP. In addition, minimum toxicities are expected by this method. As demonstrated in our study, the elderly patients who need R-CHOP are increasing. In this context, our data provide a valuable insight into the total strategy of lymphoma treatment.

Clinical trial identification

Legal entity responsible for the study

Chiba Cancer Center


Chiba Cancer Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings